SYNB011128 / Syneron Tech - LARVOL DELTA

SYNB011128: A novel bispecific peptide-drug-conjugate targeting EGFR and CAIX (AACR 2025) - "Additionally, SYNB011128 showed efficacy in models of Osimertinib-resistant non-small cell lung cancer (NSCLC). In summary, PDC SYNB011128 effectively targets both EGFR and CAIX, utilizing multiple anti-cancer mechanisms and achieving deep tumor penetration, which may lead to robust clinical efficacy. By binding to two cancer antigens to enhance tumor selectivity over normal tissues, and a pharmacokinetic profile of sustained tumor accumulation vs a short blood half-life, SYNB011128 may also have an improved safety margin."

Colon Cancer • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CA9 • EGFR